{"entity":{"id":"stephan-grupp","kind":"person","name":"Stephan A. Grupp","aka":[],"tldr":"Treated the first child with CAR-T cells and led ELIANA, the trial behind the first CAR-T approval.","summary":"Stephan Grupp treated Emily Whitehead, the first child to receive CD19 CAR-T cells, in 2012 and led the CHOP trials and the global ELIANA study that won tisagenlecleucel the first-ever CAR-T approval in 2017 for relapsed paediatric ALL. He identified tocilizumab as the treatment for cytokine release syndrome, which made CAR-T deliverable, and directs cellular therapy at CHOP.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Stephan_Grupp","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Grupp%20SA%5BAuthor%5D%20tisagenlecleucel"}],"tags":["cell-therapy","car-t","paediatric"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":["car-t"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":["chop","penn-abramson"],"pathways":[],"terms":[],"trials":["eliana"],"people":[],"bottlenecks":[],"keyPapers":["paper-eliana-tisagenlecleucel-nejm-2018","paper-maude-ctl019-all-nejm-2014"],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Cellular Therapy and Transplant Section, Children's Hospital of Philadelphia; Professor of Pediatrics, University of Pennsylvania","institutionId":"chop","specialisms":["Paediatric CAR T-cell therapy","Acute lymphoblastic leukaemia","Cytokine release syndrome","Cellular therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Grupp%20SA%5BAuthor%5D%20tisagenlecleucel"}],"papers":[{"title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","journal":"NEJM","year":2013,"doi":"10.1056/NEJMoa1215134"},{"title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia (ELIANA)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1709866"},{"title":"Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL","journal":"New England Journal of Medicine","year":2014,"url":"https://doi.org/10.1056/NEJMoa1407222","doi":"10.1056/NEJMoa1407222"}],"orcid":"0000-0001-8030-7595"},"route":"/people/stephan-grupp/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"institution":[{"id":"penn-abramson","kind":"institution","name":"Abramson Cancer Center, University of Pennsylvania","route":"/institutions/penn-abramson/"},{"id":"chop","kind":"institution","name":"Children's Hospital of Philadelphia","route":"/institutions/chop/"}],"trial":[{"id":"eliana","kind":"trial","name":"ELIANA","route":"/trials/eliana/"}],"paper":[{"id":"paper-eliana-tisagenlecleucel-nejm-2018","kind":"paper","name":"ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL","route":"/key-papers/paper-eliana-tisagenlecleucel-nejm-2018/"},{"id":"paper-maude-ctl019-all-nejm-2014","kind":"paper","name":"Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL","route":"/key-papers/paper-maude-ctl019-all-nejm-2014/"}]}}